Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users ...

Fasedienol is a first-in-class pherine nasal spray that is designed to modulate the olfactory-limbic amygdala fear and anxiety neurocircuits.

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

The Viaskin Peanut patch showed clinically meaningful desensitization and a favorable safety profile in young children with peanut allergy.

Since 1991, the CDC had recommended that all newborns receive a hepatitis B shot within 24 hours of birth to prevent early infections. The change follows a vote earlier this month by the CDC’s vaccine ...

GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM ...

Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...

The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).